Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A clinical study of STI-4398 (COVIDTRAP™ Protein) for potential prevention and treatment of SARS-COV-2 Coronavirus disease(COVID-19)

Trial Profile

A clinical study of STI-4398 (COVIDTRAP™ Protein) for potential prevention and treatment of SARS-COV-2 Coronavirus disease(COVID-19)

Status: Planning
Phase of Trial: Phase I

Latest Information Update: 26 Mar 2020

At a glance

  • Drugs STI 4398 (Primary)
  • Indications COVID 2019 infections
  • Focus Adverse reactions; Therapeutic Use
  • Most Recent Events

    • 26 Mar 2020 New trial record

Trial Overview

Purpose

This study will evaluate STI-4398 (COVIDTRAP™ Protein) for potential prevention and treatment of SARS-COV-2 Coronavirus disease(COVID-19).

Diseases Treated

Indication Qualifiers Patient Segments
COVID 2019 infections prevention, treatment -

Subjects

  • Subject Type patients & volunteers
  • Sex male & female

Trial Details

Organisations

  • Affiliations Sorrento Therapeutics

Trial Dates

Other Details

  • Design prospective
  • Phase of Trial Phase I
  • Location USA
  • Focus Adverse reactions; Therapeutic Use

Interventions

Drugs Route Formulation
STI 4398Primary Drug
-
-

STI-4398 (COVIDTRAP™ Protein)

Trial History

Event Date Event Type Comment
26 Mar 2020 New trial record New trial record Updated 26 Mar 2020

References

  1. Sorrento Therapeutics. SORRENTO DEVELOPS STI-4398 (COVIDTRAP(Tm) PROTEIN) FOR POTENTIAL PREVENTION AND TREATMENT OF SARS-COV-2 CORONAVIRUS DISEASE (COVID-19). Media-Rel 2020;.

    Media Release
Back to top